PBT2

Related by string. * * Prana PBT2 *

Related by context. All words. (Click for frequent words.) 64 Phenserine 63 ANAVEX #-# [003] 62 BNC# 62 mGluR2 NAM 62 ISIS # 61 R#/MEM # 61 INCB# [001] 61 ONCONASE R 61 davunetide 61 ThGRF 61 tezampanel 60 TRIOLEX 60 SRT# [003] 60 Anavex #-# 60 Phenoptin 59 ProSavin 59 vascular disrupting agent 59 NGX# 59 #ME# 59 IL# PE#QQR 59 Symadex 59 Tasimelteon 59 Cintredekin Besudotox 59 Panzem 59 Phase Ib clinical 59 LEP ETU 59 CYT# 59 Sym# 59 safinamide 59 eprotirome 59 neuroprotective 59 mertansine 58 PEG SN# 58 phase IIa clinical 58 ATL# [001] 58 ADX# 58 Mipomersen 58 Phase IIa clinical 58 PXD# 58 preclinical 58 AZILECT R 58 Posiphen 58 ELND# 58 preclinical studies 58 Tyrima 58 Safinamide 58 GAMMAGARD 58 Factor VIIa 58 davunetide intranasal AL 58 Phase Ib study 58 Rasagiline 58 riociguat 58 Bicifadine 58 LY# [003] 58 TriRima 58 OXi# 58 tanespimycin 58 tafamidis 57 Serdaxin 57 MGCD# [001] 57 oral prodrug 57 elotuzumab 57 LY# [002] 57 LE SN# 57 GGF2 57 metaglidasen 57 Archexin 57 anticancer agent 57 PSN# [002] 57 Tovaxin 57 Cogane 57 methylnaltrexone 57 adipiplon 57 Androxal TM 57 EndoTAG TM -1 57 AEG# 57 Valortim ® 57 teduglutide 57 Zerenex 57 GLP toxicology studies 57 siRNA therapeutics 57 torezolid phosphate 57 RDEA# 57 Phase IIb trials 57 LE DT 57 Traficet EN 57 DXL# 57 Pimavanserin 57 PS# [001] 57 SGS# 57 arimoclomol 56 IRX 2 56 RhuDex 56 Desmoteplase 56 selective androgen receptor modulator 56 CCX# 56 PRTX 56 APOPTONE 56 NTx TM -# 56 Avicena 56 PDE4 inhibitor 56 MEK inhibitor 56 fibrotic disease 56 Triolex 56 Trofex 56 MEK inhibitor RDEA# 56 Guanilib 56 huC# DM4 56 PRX # 56 CBLC# 56 laquinimod 56 Liraglutide 56 Plicera 56 MYDICAR 56 eniluracil 56 JAK inhibitor 56 phase IIb 56 Valdoxan 56 bafetinib 56 YONDELIS 56 bardoxolone 56 Bortezomib 56 MAP# 56 Atiprimod 56 alagebrium 56 ReN# 56 Preclinical studies suggest 56 tiapamil 56 GRN# 55 Phase #b/#a 55 CRx 55 PSMA ADC 55 Valortim 55 TRO# 55 eltrombopag 55 PD LID 55 vidofludimus 55 IMA# 55 TELINTRA 55 ELND-#/AZD-# 55 phase IIa 55 OHR/AVR# 55 ADAGIO study 55 nonclinical studies 55 HuLuc# 55 Dapagliflozin 55 ASONEP 55 cediranib 55 Memryte 55 Synavive 55 CA4P 55 XmAb# 55 CoFactor 55 oral FTY# 55 TH# [003] 55 axitinib 55 ANG# 55 MEK inhibitors 55 Neo Kidney Augment 55 CORT # 55 tasimelteon 55 clioquinol 55 ATL/TV# 55 Azedra 55 anticancer compound 55 anti amnesic 55 lomitapide 55 DR Cysteamine 55 uricase 55 Phase IIa 55 GRN#L 55 lurasidone 55 QLT# 55 triphendiol 55 PLK1 SNALP 55 CR# vcMMAE 55 cangrelor 55 Curaxin CBLC# 55 galanin 55 Fx #A 55 Miraxion 55 SNT MC# 55 diabetic nephropathy 55 Cetrorelix 55 dirucotide 55 immune modulatory 55 preclinical toxicology 55 cannabinor 55 exon skipping 55 PRT# 55 ancrod 55 CRLX# 55 enzastaurin 55 HDAC inhibitors 55 GLYX 55 SAR# [002] 55 midstage clinical 55 phase IIb clinical 54 TMC# [002] 54 Ocrelizumab 54 IAP inhibitors 54 cMET 54 TKM ApoB 54 ICA # 54 JAK3 54 HQK 54 Ostarine 54 Alzhemed 54 SAR# [004] 54 pharmacological chaperone 54 AP# [003] 54 Chrysalin 54 HuMax CD# 54 Phase IIa trials 54 R#/MEM 54 Onconase 54 CCR9 antagonist 54 omecamtiv mecarbil 54 tezampanel NGX# 54 LAF# 54 Phase 2a trial 54 Phase 2a 54 otelixizumab 54 orally bioavailable 54 Phase 2a clinical 54 Genasense ® oblimersen 54 NV1FGF 54 AVN# [001] 54 SIRT1 activators 54 angiogenesis inhibitor 54 atacicept 54 tarenflurbil 54 Locteron ® 54 FTY# 54 Angiolix 54 entinostat 54 ocrelizumab 54 BAY #-# 54 DG# [001] 54 Phase IIB 54 OvaRex ® MAb 54 EGS# 54 sulodexide 54 ApoB SNALP 54 Cleviprex TM clevidipine 54 insulin sensitizers 54 investigational humanized monoclonal antibody 54 iroxanadine 54 Ampakine 54 GALNS 54 Virulizin R 54 DP b# 54 BRAF inhibitor 54 nicotinic alpha 7 54 ZOLINZA 54 Phase 2a clinical trials 54 PCK# 54 novel VDA molecule 54 antisense drug 54 Phase IIIb clinical 54 L DOS# 54 ZFP Therapeutic 54 disease modifying 54 ibudilast 54 cholinesterase inhibitors 54 ataluren 54 deacetylase inhibitors 54 acetylcholinesterase 54 Prodarsan ® 54 Tolvaptan 54 Lisofylline 54 Kevetrin 54 trodusquemine 54 ostarine 54 Chemokine 54 Dasatinib 54 memantine 54 Virulizin ® 54 TLR agonists 54 HuMax EGFr 54 trastuzumab DM1 T DM1 54 Phase 1b 54 allosteric modulator 54 PLX cells 54 Relivar 54 MDV# 54 ASA# 54 TOCOSOL Paclitaxel 53 pan HDAC inhibitor 53 dimebon 53 oral bioavailability 53 bevirimat 53 orally dosed 53 alvespimycin 53 EDEMA3 trial 53 refractory gout 53 vascular disrupting 53 Phase Ib 53 GSK# [002] 53 Tarvacin 53 Panzem R 53 RGB # 53 INT# [002] 53 CEQ# 53 #beta HSD1 53 Phase IIb clinical 53 GRNCM1 53 insulin sensitizing 53 partial agonist 53 SUVN 53 RhuDex ® 53 Kevetrin ™ 53 PF # [001] 53 Golimumab 53 JAK2 inhibitor 53 Microplasmin 53 Sapacitabine 53 JAK inhibitors 53 Cethromycin 53 IL# PE 53 volociximab 53 synthetic retinoid 53 ENMD # 53 VA# [002] 53 Curaxin 53 Aviptadil 53 Zemiva TM 53 epothilone 53 pralatrexate 53 FOLOTYN ® 53 preclinically 53 CDK inhibitor 53 preclinical pharmacokinetic 53 RPL# 53 darapladib 53 JAK1 53 rxRNA 53 Vilazodone 53 Xanafide 53 Stimuvax R 53 AZD# 53 OX1 53 Lisofylline LSF 53 Viprinex 53 Nasulin 53 Laquinimod 53 glufosfamide 53 HGS# 53 liposomal formulation 53 Anacetrapib 53 TLK# 53 EP #R 53 forodesine 53 liprotamase 53 KNS # 53 Enkephalin 53 confirmatory Phase III 53 pertuzumab 53 polymerase inhibitor 53 Dalbavancin 53 ALN RSV# 53 CGEN # 53 Tezampanel 53 ALKS 53 Litx 53 CRF1 receptor antagonist 53 therapeutic monoclonal antibody 53 SPC# [001] 53 Squalamine 53 Hedgehog signaling pathway 53 elacytarabine 53 obatoclax 53 DU #b 53 Abeta# 53 ulimorelin 53 DACH platinum 53 proteasome inhibitor 53 bapineuzumab 53 Opexa 53 rindopepimut 53 OXIGON TM 53 systemically administered 53 Actilon 53 Phase IIa trial 53 Marqibo TM 53 cancer cachexia 53 dexpramipexole 53 non nucleoside HCV 53 NN# [001] 53 Exelixis XL# 53 daclizumab 53 Phase 1b clinical 52 IMC #B 52 HGS ETR1 52 ALTU 52 MB# [004] 52 ganetespib 52 IL #E 52 CINTREDEKIN BESUDOTOX 52 Amplimexon 52 Dimebon 52 NexACT 52 MNTX 52 talabostat 52 Menerba 52 vorinostat 52 MYDICAR ® 52 diabetic neuropathic pain 52 elesclomol 52 Protexia ® 52 ProLindac 52 Lixivaptan 52 ImmunoVEX HSV2 52 DAVANAT ® 52 urocortin 2 52 calcitonin 52 IIa trial 52 teriflunomide 52 antisense inhibition 52 LT NS# 52 Fibrillex TM 52 ZYBRESTAT 52 6R BH4 52 OncoVEX 52 oral gallium 52 GLPG# 52 ALN VSP 52 Exelixis compounds 52 IND submission 52 VAPRISOL 52 SGLT inhibitors 52 Phase IIb 52 Aurexis 52 phase IIb trial 52 edifoligide 52 CTAP# Capsules 52 Azedra TM 52 AMPAKINE R 52 Debio 52 MAXY G# 52 Onalta 52 vismodegib 52 Alzhemed TM 52 talactoferrin 52 BCX# 52 olaparib 52 AeroLEF TM 52 Saforis 52 disease progression 52 Tamibarotene 52 COPREXA 52 Solulin 52 HGS ETR2 52 vilazodone 52 MAGE A3 ASCI 52 Cethrin 52 KineMed 52 PEG PAL 52 investigational compound 52 SparVax TM 52 AMD# [003] 52 deforolimus 52 Carfilzomib 52 TBC# 52 IDX# 52 Valortim R 52 MAXY alpha 52 APD# 52 sd rxRNA 52 PTP 1B 52 GeneICE 52 masitinib 52 indibulin 52 GED aPC 52 bremelanotide 52 schizophrenia CIAS 52 cancer immunotherapies 52 ALN TTR 52 ALN TTR# 52 nitazoxanide 52 HCV protease inhibitor 52 Phase #b/#a trial 52 registrational 52 Perifosine 52 OncoVEX GM CSF 52 HDL Mimetic Peptide 52 teplizumab 52 TRX1 52 HCV protease 52 AKT inhibitor 52 Corlux 52 AQ4N 52 Adenosine Therapeutics 52 IMGN# 52 AERx iDMS 52 trastuzumab DM1 52 Homspera 52 Ceflatonin 52 FBPase 52 Angiocept 52 hypoxia selective 52 multitargeted 52 siRNA therapeutic 52 INCB# [002] 52 NTDDS 52 induce apoptosis 52 GFT# 52 Phase 1a clinical 52 PREOS 52 rBChE 52 sd rxRNA compounds 52 Bendavia 52 Phase Ib II 52 RG# [001] 52 mTOR inhibition 52 PrevOnco 52 Interferon alpha 52 MLN# 52 Asentar 52 MBP# [001] 52 generation purine nucleoside 52 ANAVEX 52 Exherin TM 52 novel anticancer 52 reslizumab 52 ularitide 52 Oral NKTR 52 signal transduction inhibitor 52 antisense 52 #D#C# 52 iSONEP 52 antisense oligonucleotide 52 Amigal 52 Aptivus ® 52 Naproxcinod 52 Insegia 52 Cobalamin 52 Linaclotide 52 integrase inhibitor 52 tolevamer 52 menadione 52 immunomodulatory 51 rHuPH# 51 LymphoStat B 51 Cloretazine R VNP#M 51 Phase III clinical 51 nanoviricides 51 BZL# 51 Boceprevir 51 clinical trials 51 MOZOBIL 51 Ron Bentsur 51 nalbuphine ER 51 KB# [002] 51 MOR# 51 DPX Survivac 51 selective modulator 51 Phase III clinical trials 51 PARP inhibitors 51 Marqibo 51 PHX# 51 Apixaban 51 Scancell 51 decitabine 51 ocular formulation 51 Phase 2b clinical 51 Spiro Rombotis President 51 tyrosine kinase inhibitor 51 CG# [003] 51 NOXXON 51 Sulonex 51 telomerase therapeutic 51 Personalized Immunotherapy 51 NEUMUNE 51 anti CD3 51 protein tyrosine phosphatase 1B 51 favorable pharmacokinetic profile 51 R roscovitine 51 BiTE 51 antiangiogenic activity 51 A3 adenosine receptor 51 Phase 2b trial 51 selective agonist 51 PROSTVAC TM 51 proteasome inhibitors 51 ganaxolone 51 targeted radiotherapeutic 51 Nanobody 51 GAP #B# 51 TRV# [001] 51 TOLAMBA 51 glucokinase activator 51 Phase 2a Clinical Trial 51 miR #a [002] 51 Cloretazine ® 51 mu opioid receptor antagonist 51 Nasdaq IDRA today 51 aurora kinase 51 PROMACTA 51 pomalidomide 51 maturation inhibitor 51 Azixa 51 THR beta agonist 51 Preclinical studies 51 XL# [003] 51 EOquin TM 51 Dacogen injection 51 HE# [002] 51 Flurizan 51 gamma secretase inhibitor 51 ALD# 51 Solazed TM 51 2DG 51 Aplidin R 51 Neo Kidney Augment ™ 51 preclinical efficacy 51 ALN PCS 51 Aplidin 51 generation URAT1 inhibitor 51 SERMs 51 MAXY VII 51 hGH CTP 51 Pertuzumab 51 ALGRX 51 Addex 51 Phase 2b clinical trials 51 selective inhibition 51 antiplatelet agent 51 IgG1 antibody 51 Ambrisentan 51 vascular disrupting agents 51 PEGylated 51 RLY# 51 evaluating tivozanib 51 Tarvacin TM 51 carfilzomib 51 muraglitazar 51 INS# [001] 51 PEG Interferon lambda 51 Nuvion 51 Riquent 51 investigational pan BCR 51 DOS# 51 ruxolitinib 51 hedgehog pathway 51 small molecule tyrosine 51 histone deacetylase inhibitors 51 TKM PLK1 51 AMPAKINE CX# 51 systemic RNAi 51 PROCHYMAL 51 DCVax R 51 glucagon receptor 51 lorvotuzumab mertansine 51 PLX# 51 perifosine 51 small molecule defensin 51 Enzastaurin 51 opioid receptor antagonist 51 bortezomib Velcade 51 OvaRex R 51 XL# XL# XL# XL# 51 CTLA 4 51 Ceflatonin R 51 L BLP# 51 ISTODAX 51 bicifadine 51 PKC# 51 Recombinant Human 51 relapsing remitting multiple sclerosis 51 immune modulation 51 Hsp# inhibition 51 VitiGam 51 Tesetaxel 51 CK # novel 51 Rotigotine 51 KRN# 51 Catena ® 51 Protexia R 51 cysteamine 51 omega interferon 51 bexarotene 51 AEGR 51 TREANDA 51 neuroprotective properties 51 ImmunoCellular Therapeutics 51 TACI Ig 51 Locteron 51 MAb 51 LNPs 51 antitumor effects 51 pharmacodynamic properties 51 Pazopanib 51 Romidepsin 51 donepezil 51 Sphingomab 51 NNR Therapeutics 51 ANAVEX #-# [001] 51 mGluR5 NAM 51 HDAC Inhibitor 51 cetuximab Erbitux 51 HCV protease inhibitors 51 pharmacokinetic PK 51 VEGF Trap 51 elvitegravir 51 OMNARIS HFA 51 histone deacetylase HDAC inhibitor 51 novel prodrug 51 Tanespimycin 51 Zoraxel 51 aldehyde dehydrogenase ALDH2 deficiency 51 Kahalalide F 51 Phase IIa clinical trials 51 celgosivir 51 P#X# 51 OxBC 51 maximally tolerated dose 51 Telintra 51 protein kinase inhibitor 51 VEGF inhibitors 51 drug GAP #B# 51 Unit Dose Budesonide 51 samalizumab 51 HuMax CD4 51 Neuradiab 51 Adentri 51 ZD# [001] 50 generation antisense 50 investigational therapies 50 TELCYTA 50 pharmacokinetic PK profile 50 HspE7 50 AMPAKINE 50 Can Fite 50 PI3K/Akt pathway inhibitor 50 cobiprostone 50 viral kinetics 50 CD# antibody [001] 50 Alzheimer disease AD 50 canakinumab 50 Aurora Kinase 50 SARMs 50 Thiarabine 50 HCV polymerase inhibitors 50 VEGF receptor 50 NeuroVax TM 50 muscarinic 50 Interferon beta 1a 50 Ridaforolimus 50 Vandetanib 50 imetelstat 50 leading oral taxane 50 velafermin 50 somatostatin analogue 50 Surfaxin LS 50 lipidoid 50 Virulizin 50 humanized monoclonal 50 Axona 50 orally administered inhibitor 50 RenaZorb TM 50 Hsp# Inhibitor 50 NP2 Enkephalin 50 TNFa 50 Apoptone 50 mapatumumab 50 CYC# 50 Alfimeprase 50 humanized anti 50 custirsen 50 delafloxacin 50 HuCNS SC cells 50 phase 2a 50 next generation URAT1 50 fosbretabulin 50 erlotinib Tarceva 50 liver fibrosis 50 Phase Ia 50 Vidofludimus 50 trial evaluating PRX# 50 nucleotide analog 50 subcutaneous formulation 50 TLR9 agonist 50 Alocrest 50 rhIL 7 50 Coversyl 50 Soliris eculizumab 50 SYGNIS 50 Trastuzumab 50 clinical pharmacology studies 50 Homspera TM 50 adecatumumab 50 humanized antibody 50 Versartis 50 clinical trial 50 ALS #-# 50 BRAF kinase 50 Ramoplanin 50 bardoxolone methyl 50 PN# [001] 50 midstage studies 50 Phase IIb trial 50 Aflibercept 50 Monoclonal Antibody 50 Fc fusion protein 50 neurodegeneration 50 PI3K/mTOR 50 deferiprone 50 phase Ib 50 Maraviroc 50 lumiliximab 50 CIMZIA TM 50 rFVIIIFc 50 PDE4 inhibitors 50 antitumor efficacy 50 SILENOR TM 50 epigenetic therapies 50 SGLT2 inhibitors 50 almorexant 50 Ramelteon 50 TLR8 50 peripherally acting 50 Novel Oral 50 PsychoGenics 50 Tarvacin Anti Viral 50 2 methoxyestradiol 50 RP# [002] 50 semagacestat 50 XL# XL# XL# 50 visilizumab 50 IAP inhibitor 50 Ampligen ® 50 milatuzumab 50 beta Estradiol 50 TLR antagonists 50 insulin sensitizer 50 Tarceva TM 50 candidate CRLX# 50 INCB# [003] 50 neuronal dysfunction 50 TG# [001] 50 mGluR5 negative 50 BRIM2 50 oxymorphone ER 50 OTCBB CTIX 50 Trizytek 50 kinase inhibitor 50 baminercept 50 MGd 50 p# inhibitors 50 albiglutide 50 biologic therapies 50 Poly ICR 50 Intravenous CP 50 TRIOLEX ™ 50 Angiotensin 50 DNA RNA Medicines 50 ALV# 50 tranilast 50 prostone 50 monoclonal antibody 50 Thiovir 50 investigational drug 50 DFMO 50 neuroprotectant 50 RNAi therapeutic targeting PCSK9 50 Anthim 50 Parkinson disease levodopa induced 50 sodium glucose cotransporter 50 TYZEKA 50 Bezielle 50 Vicriviroc 50 GDIR 50 seliciclib CYC# 50 PEGPH# 50 brivaracetam 50 pafuramidine 50 EVIZON TM squalamine lactate 50 Phase 2b study 50 entacapone 50 TG# [003] 50 allosteric modulator NAM 50 Pharmos pipeline 50 pharmacodynamic PD 50 isoform selective 50 gastrin 50 VRX# [002] 50 anti fibrotic 50 Zybrestat 50 tubulin inhibitor 50 therapeutic monoclonal antibodies 50 CD# CEA 50 Affibody 50 dacetuzumab 50 Bruton tyrosine kinase Btk 50 sorafenib Nexavar 50 cilengitide 50 AAG geldanamycin analog 50 IND enabling 50 CIMZIA ™ 50 Regado 50 vivo validation 50 TNFα 50 lintuzumab 50 Aganocide 50 SCH # 50 AA amyloidosis 50 vosaroxin 50 Radilex 50 GSK # 50 investigational monoclonal antibody 50 Aliskiren 50 RH1 50 amyloid β 50 intranasal formulation 50 PRX# 50 Lenalidomide 50 CaPre TM 50 Factor Xa inhibitor 50 Chemophase 50 Aurora kinase 50 Resten NG 50 oral JAK1 50 depsipeptide 50 ON #.Na 50 Trophos 50 CCR5 antagonist 49 dyskinesia PD LID 49 Hedgehog antagonist 49 LymphoStat B belimumab 49 NKTR 49 bortezomib Velcade ® 49 tivozanib 49 LPA1 receptor 49 SGLT Inhibitors 49 Presents Preclinical Data 49 Prodarsan R 49 levodopa carbidopa 49 demonstrated antitumor activity 49 Trofex TM 49 Pharmos proprietary 49 Sulonex TM 49 humanized monoclonal antibodies 49 Hsp# inhibitor 49 targeting CD# 49 Cannabinor 49 pharmacokinetic properties 49 antitumor 49 Nexavar sorafenib 49 selective androgen receptor modulators 49 cathepsin K inhibitor 49 anticancer therapies 49 Atrasentan 49 Phase Ib clinical trials 49 seliciclib 49 mecamylamine 49 Voreloxin 49 antisense inhibitors 49 LSI #P 49 HepDirect 49 AEZS 49 cachexia 49 panitumumab Vectibix 49 midstage trials 49 hyperphenylalaninemia HPA due 49 Proellex TM 49 biologic therapeutics 49 donepezil Aricept 49 MORAb 49 solithromycin 49 CINOD 49 Phase 1a 49 mTOR inhibitors 49 Panzem R NCD 49 INGN 49 Nanobody ® 49 Hsp# inhibitors 49 Anticalin 49 tolerability profiles 49 vitro studies 49 HDAC inhibition 49 EndoTAG TM 49 picoplatin 49 YONDELIS R 49 AV HALT 49 flavopiridol 49 CCR2 49 gefitinib Iressa 49 rivastigmine Exelon 49 Anticalin R 49 Pervasis 49 gallium containing 49 Tβ4 49 RAV# 49 ENMD 49 rFIXFc 49 Phase IIb clinical trials 49 BGC# 49 ongoing Phase 1b

Back to home page